ProfileGDS5678 / 1453487_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 73% 76% 73% 74% 76% 76% 78% 79% 75% 75% 74% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7360873
GSM967853U87-EV human glioblastoma xenograft - Control 24.7087173
GSM967854U87-EV human glioblastoma xenograft - Control 35.1013776
GSM967855U87-EV human glioblastoma xenograft - Control 44.8330873
GSM967856U87-EV human glioblastoma xenograft - Control 54.8306374
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9687176
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0082576
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4200978
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5735379
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0493575
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9142475
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8545974
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8974775
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8779275